Verapamil Increases the Apolipoprotein-Mediated Release of Cellular Cholesterol by Induction of ABCA1 Expression Via Liver X Receptor-Independent Mechanism

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 3, 2004, Pages 519-525

  Suzuki, Shogo ^a,d   Nishimaki Mogami, Tomoko ^b   Tamehiro, Norimasa ^b   Inoue, Kazuhide ^b   Arakawa, Reijiro ^a   Abe Dohmae, Sumiko ^a   Tanaka, Arowu R ^c   Ueda, Kazumitsu ^c   Yokoyama, Shinji ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d CHUBU NATIONAL HOSPITAL   (Japan)

Author keywords

ABCA1; Apolipoprotein; Calcium channel blocker; Cholesterol; HDL; Macrophage; Verapamil

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DEXVERAPAMIL; GENE PRODUCT; HIGH DENSITY LIPOPROTEIN; LIVER X RECEPTOR; LUCIFERASE; MESSENGER RNA; NICARDIPINE; NIFEDIPINE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; CHOLESTEROL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG MECHANISM; GENETIC TRANSFECTION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; APOLIPOPROTEIN A-I; ATP-BINDING CASSETTE TRANSPORTERS; BETA-CYCLODEXTRINS; BUCLADESINE; CALCIUM CHANNEL BLOCKERS; CELL LINE; CHOLESTEROL; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; HYDROXYCHOLESTEROLS; LIPOPROTEINS; LIPOPROTEINS, HDL; LOVASTATIN; MACROPHAGES; MICE; NICARDIPINE; NIFEDIPINE; PHOSPHOLIPIDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; STEREOISOMERISM; TRANSFECTION; VERAPAMIL;

EID: 1542373718     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000117178.94087.ba     Document Type: Article

References (55)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-714.
2. Gordon DJ, Rifkind BM. High density lipoprotein - The clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
3. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
4. Yokoyama S. Release of cellular cholesterol: Molecular mechanism for cholesterol homeostasis in cells and in the body. Biochim Biophys Acta. 2000;1529:231-244.
5. Hara H, Yokoyama S. Interaction of free apolipoproteins with macrophages: Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem. 1991;266:3080-3086.
6. Komaba A, Li Q, Hara H, Yokoyama S. Resistance of smooth muscle cells to assembly of high density lipoproteins with extracellular free apolipoproteins and to reduction of intracellularly accumulated cholesterol. J Biol Chem. 1992;267:17560-17566.
7. Francis GA, Knopp RH, Oram JF. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease. J Clin Invest. 1995;96:78-87.
8. Remaley AT, Schumacher UK, Stonik JA, Farsi BD, Nazih HB, Brewer HBJ. Decreased reverse cholesterol transport from Tangier disease fibroblasts: Acceptor specificity and effect of brefeldin on lipid efflux. Arterioscler Thromb Vasc Biol. 1997;17:1813-1821.
9. Tsujita M, Yokoyama S. Selective inhibition of free apolipoprotein-mediated cellular lipid efflux by probucol. Biochemistry. 1996;35: 13011-13020.
10. Tsujita M, Tomimoto S, Okumura-Noji K, Okazaki M, Yokoyama S. Apolipoprotein-mediated cellular cholesterol/phospholipid efflux and plasma high density lipoprotein level in mice. Biochim Biophys Acta. 2000;1485:199-213.
11. Bodzioch M, Orso E, Klucken J, Langmann T, Böttcher A, Diederich W, Drobnik W, Barlage S, Büchler C, Porsch-Özcürümez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G. The gene encoding ATP-binding cassette transponer 1 is mutated in Tangier disease. Nat Genet. 1999;22:347-351.
12. Brooks-Wilson A, Marcil M, Clee SM, Zhang L-H, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HOF, Loubser O, Ouelette BFF, Fichter K, Ashbourne-Excoffon KJD, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJP, Genest J, Jr., Hayden MR. Mutations in ABC 1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999; 22:336-345.
13. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette J-C, Deleuze J-F, Brewer HB, Duverger N, Denefle P, Assmann G. Tangier disease is caused by mutations in the gene encoding ATP binding-cassette transporter 1. Nat Genet. 1999;22:352-355.
14. Wang N, Silver DL, Costet P, Tall AR. Specific binding of apoA-I, enhanced cholesterol efflux and altered plasma membrane morphology in cells expressing ABCA1. J Biol Chem. 2000;275:33053-33058.
15. Tanaka AR, Ikeda Y, Abe-Dohmae S, Arakawa R, Sadanami K, Kidera A, Nakagawa S, Nagase T, Aoki R, Kioka N, Amachi T, Yokoyama S, Ueda K. Human ABCA1 contains a large amino-terminal extracellular domain homologous to an epitope of Sjögren's syndrome. Biochem Biophys Res Commun. 2001;283:1019-1025.
16. Singaraja RR, Bocher V, James ER, Clee SM, Zhang L-H, Leavitt BR, Tan B, Brooks-Wilson A, Kwok A, Bissada N, Yang Y-z, Liu G, Tafuri SR, Fievet C, Wellington CL, Staels B, Hayden MR. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and apoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem. 2001;276:33969-33979.
17. Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD, Cain WJ, Fruchart-Najib J, Neufeld ED, Remaley AT, Brewer HB, Jr., Santamarina-Fojo S. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest. 2001;108:303-309.
18. Joyce CW, Amar MJ, Lambert G, Vaisman BL, Paigen B, Najib-Fruchart J, Hoyt RF, Jr., Neufeld ED, Remaley AT, Fredrickson DS, Brewer HB, Jr., Santamarina-Fojo S. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci U S A. 2002;99: 407-412.
19. Singaraja RR, Fievet C, Castro G, James ER, Hennuyer N, Clee SM, Bissada N, Choy JC, Fruchart JC, McManus BM, Staels B, Hayden MR. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest. 2002;110:35-42.
20. Langmann T, Klucken J, Reil M, Liebisch G, Luciani M-F, Chimini G, Kaminski WE, Schmitz G. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophage. Biochem Biophys Res Commun. 1999;257:29-33.
21. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 2000;275:28240-28245.
22. Schwartz K, Lawn RM, Wade DP. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun. 2000;274:794-802.
23. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A 2000; 97:12097-12102.
24. Arakawa R, Abe-Dohmae S, Asai M, Ito J, Yokoyama S. Involvement of caveolin-1 in cholesterol-enrichment of HDL during its assembly by apolipoprotein and THP-1 cells. J Lipid Res. 2000;41:1952-1962.
25. Smith JD, Miyata M, Ginsberg M, Grigaux C, Shmookler E, Plump AS. Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from macrophage cell line to apolipoprotein acceptors. J Biol Chem. 1996;271:30647-30655.
26. Abe-Dohmae S, Suzuki S, Wada Y, Aburatani H, Vance DE, Yokoyama S. Characterization of apolipoprotein-mediated HDL generation induced by cAMP in a murine macrophage cell line. Biochemistry 2000;39: 11092-11099.
27. Oram JF, Lawn RM, Garvin MR, Wade DP. ABCA1 is the cAMP-induced apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem. 2000;34508-34511.
28. Panousis CG, Evans G, Zuckerman SH. TGF-beta increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells: opposing the effects of IFN-gamma. J Lipid Res. 2001;42:856-863.
29. Kaplan R, Gan X, Menke JG, Wright SD, Cai TQ. Bacterial lipopolysaccharide induces expression of ABCA1 but not ABCG1 via an LXR-independent pathway. J Lipid Res. 2002;43:952-959.
30. Panousis CG, Zuckerman SH. Interferon-gamma induces downregulation of Tangier disease gene (ATP-binding-cassette transporter 1) in macrophage-derived foam cells. Arterioscler Thromb Vasc Biol. 2000;20: 1565-1571.
31. Arakawa R, Yokoyama S. Helical apolipoproteins stabilize ATP-bindiug cassette transporter A1 by protecting it from thiol protease-mediated degradation. J Biol Chem. 2002;277:22426-22429.
32. Wang Y, Oram JF. Unsaturated Fatty Acids Inhibit Cholesterol Efflux from Macrophages by Increasing Degradation of ATP-binding Cassette Transporter A1. J Biol Chem. 2002;277:5692-5697.
33. Suzuki S, Abe-Dohmae S, Fukutomi T, Ito S, Itoh M, Yokoyama S. Enhancement of the cAMP-induced apolipoprotein-mediated cellular lipid release by calmodulin inhibitors W7 and W5 from RAW 264 mouse macrophage cell line cells. J Cardiovasc Pharmacol. 2000;36:609-616.
34. Waters D, Lesperance J. Calcium channel blockers and coronary atherosclerosis: from the rabbit to the real world (Review). Am Heart J. 1994;128:1309-1316.
35. Mancini GB. Antiatherosclerotic effects of calcium channel blockers (Review). Prog Cardiovasc Dis. 2002;45:1-20.
36. Schroeder JS, Gao SZ, Alderman EL, Hunt SA, Johnstone I, Boothroyd DB, Wiederhold V, Stinson EB. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med. 1993;328:164-170.
37. Walldius G. Effect of verapamil on serum lipoproteins in patients with angina pectoris. Acta Med Scand. 1984;681:43-48.
38. Midtbo KA. Effects of long-term verapamil therapy on serum lipids and other metabolic parameters (Review). Am J Cardiol. 1990;66:13I-15I.
39. Libretti A, Catalano M. Lipid profile during anthypertensive treatment. The SLIP Study Group. Study on Lipids with Isoptin Press. Drugs. 1993;46:16-23.
40. Stender S, Ravn H, Haugegaard M, Kjeldsen K. Effect of verapamil on accumulation of free and esterified cholesterol in the thoracic aorta of cholesterol-fed rabbits. Atherosclerosis. 1986;61:15-23.
41. Ralph P, Nakoinz I. Antibody-dependent killing of erythrocyte and tumor targets by macrophage-related cell lines: enhancement by PPD and LPS. J Immunol. 1977;119:950-954.
42. Kojima K, Abe-Dohmae S, Arakawa R, Murakami I, Suzumori K, Yokoyama S. Progesterone inhibits apolipoprotein-mediated cellular lipid release: A putative mechanism for the decrease of HDL. Biochim Biophys Acta. 2001;1532:173-184.
43. Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Kimura S, Ishibashi S, Yamada N. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol Cell Biol. 2001;21: 2991-3000.
44. Keogh AM, Schroeder JS. The antiatherogenic effects of calcium antagonists (Review). Am J Hypertens. 1991;4:512S-518S.
45. DeBose-Boyd RA, Ou J, Goldstein JL, Brown MS. Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. Proc Natl Acad Sci U S A. 2001;98:1477-1482.
46. Venkateswaran A, Repa JJ, Lobaccaro JM, Bronson A, Mangelsdorf DJ, Edwards PA. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem. 2000;275:14700-14707.
47. Kennedy MA, Venkateswaran A, Tarr PT, Xenarios I, Kudoh J, Shimizu N, Edwards PA. Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J Biol Chem. 2001;276: 39438-39447.
48. Qiu Y, Cavelier L, Chiu S, Yang X, Rubin E, Cheng JF. Human and mouse ABCA1 comparative sequencing and transgenesis studies revealing novel regulatory sequences. Genomics. 2001;73:66-76.
49. Klucken J, Büchler C, Orsó E, Kaminski WE, Porsch-Özcürümez M, Liebisch G, Kapinsky M, Diederich W, Drobnik W, Dean M, Allikmets R, Schmitz G. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci U S A. 2000;97:817-822.
50. Haidar B, Denis M, Krimbou L, Marcil M, Genest J, Jr. cAMP induces ABCA1 phosphorylation activity and promotes cholesterol efflux from fibroblasts. J Lipid Res. 2002;43:2087-2094.
51. See RH, Caday-Malcolm RA, Singaraja RR, Zhou S, Silverston A, Huber MT, Moran J, James ER, Janoo R, Savill JM, Rigot V, Zhang LH, Wang M, Chimini G, Wellington CL, Tafuri SR, Hayden MR. Protein kinase A site-specific phosphorylation regulates ATP-binding cassette A1 (ABCA1)-mediated phospholipid efflux. J Biol Chem. 2002;277: 41835-41842.
52. Santamarina-Fojo S, Peterson K, Knapper C, Qiu Y, Freeman L, Cheng JF, Osorio J, Remaley A, Yang XP, Haudenschild C, Prades C, Chimini G, Blackmon E, Francois T, Duverger N, Rubin EM, Rosier M, Denefle P, Fredrickson DS, Brewer HB, Jr. Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter. Proc Natl Acad Sci U S A. 2000;97:7987-7992.
53. Erratum. Proc Natl Acad Sci U S A. 2002;99:1098.
54. Walz G, Zanker B, Barth C, Wieder KJ, Clark SC, Strom TB. Transcriptional modulation of human IL-6 gene expression by verapamil. J Immunol. 1990;144:4242-4248.
55. Block LH, Keul R, Crabos M, Ziesche R, Roth M. Transcriptional activation of low density lipoprotein receptor gene by angiotensin-converting enzyme inhibitors and Ca(2+)-channel blockers involves protein kinase C isoforms. Proc Natl Acad Sci U S A. 1993;90: 4097-4101.